| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 475 |
| 1 | NIVOLUMAB | 191 |
| 2 | TEMOZOLOMIDE | 186 |
| 3 | CARBOPLATIN | 99 |
| 4 | IPILIMUMAB | 84 |
| 5 | PEMETREXED DISODIUM | 65 |
| 6 | PACLITAXEL | 58 |
| 7 | PACLITAXEL (AIBUMIN-BOUND) | 52 |
| 8 | PEMETREXED | 51 |
| 9 | CISPLATIN | 45 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ENSARTINIB | 1 | 0.0222 |
| 1 | EPCORITAMAB-BYSP | 22 | 0.0164 |
| 2 | LOMUSTINE | 25 | 0.0096 |
| 3 | TEMOZOLOMIDE | 186 | 0.0087 |
| 4 | DEXTROSE, SOYBEAN OIL, ELECTROLYTES, LYSINE, PHENYLALANINE, LEUCINE, VALINE, THREONINE, METHIONINE, ISOLEUCINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, PROLINE, HISTIDINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID AND TYROSINE | 3 | 0.0075 |
| 5 | LISOCABTAGENE MARALEUCEL | 6 | 0.0068 |
| 6 | CEMIPLIMAB-RWLC | 13 | 0.0062 |
| 7 | PEMBROLIZUMAB | 475 | 0.0044 |
| 8 | ELRANATAMAB-BCMM | 5 | 0.0043 |
| 9 | TALIMOGENE LAHERPAREPVEC | 5 | 0.0031 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 692 | 0.0070 |
| 1 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 25 | 0.0062 |
| 2 | Lymphocyte Activation Gene-3 Blocker [EPC] | 1 | 0.0019 |
| 3 | CTLA-4-directed Blocking Antibody [EPC] | 88 | 0.0018 |
| 4 | CD19-directed Chimeric Antigen Receptor [EPC] | 17 | 0.0017 |
| 5 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 2 | 0.0013 |
| 6 | Programmed Death Ligand-1 Blocker [EPC] | 25 | 0.0012 |
| 7 | Lipid Emulsion [EPC] | 3 | 0.0011 |
| 8 | Endoglycosidase [EPC] | 2 | 0.0011 |
| 9 | Lipid-based Polyene Antifungal [EPC] | 13 | 0.0010 |